Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 9/20 | 0.47 |
| ▸ | HTR7 | P34969 | 6/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870400 | 0.81 | ALDH1A1 (0.53) | DRD2ALDH1A1SLC6A4 | |
| SCHEMBL4872035 | 0.79 | ADRA1D (0.56) | HTR7SLC6A4 | |
| SCHEMBL31094938 | 0.77 | DRD2 (0.63) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL11567913 | 0.77 | ACHE (0.57) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL6143710 | 0.76 | DRD2 (0.62) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL4871793 | 0.75 | DRD2 (0.44) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL29930695 | 0.75 | NPSR1 (0.65) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL29086968 | 0.73 | ACHE (0.48) | ACHEDRD2DRD3HTR1AHTR7 | |
| SCHEMBL5937370 | 0.73 | DRD2 (0.49) | DRD2ALDH1A1SLC6A4 | |
| SCHEMBL5937247 | 0.72 | ADRA1D (0.52) | DRD2DRD3HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | claimed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7148235-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ACHE 210/4885DRD2 25/4885DRD3 34/4885 |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ACHE 220/4885DRD2 23/4885DRD3 32/4885 |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ACHE 220/4885DRD2 23/4885DRD3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.